Browse the list of Consortia below to learn more about each CAVD Grant.
Alt: Physiologically Relevant and Rapidly Generated HIV-1 Vaccine Mouse Models Alter: A Generic Approach to Optimizing the Antigenicity of HIV-1 Envelope Immunogens
Barouch: Epitope-Modified Env Trimers for Induction of Heterologous Tier 2 NAbs Barouch: Therapeutic Efficacy of Potent Broadly Neutralizing mAbs for HIV-1 Eradication Busch: Validation of Existing and Ultra-Sensitive Assays for Qualifying HIV Persistence
Return to top
Corey: Support for HVTN 702 Crotty: Improving the identification of epitope-specific precursor naive B cells in the human B cell repertoire
Farzan: Preventing HIV-1 transmission with eCD4-Ig Feinberg: IAVI Neutralizing Antibody Consortium
Gaiha: Multi-networked T cell epitope vaccine for global HIV prevention and therapy Gallo: FLSC Phase I & II Clinical Trials Gottardo: VISC
Hassell: CAVD Alliance ManagementHassell: Vaccine Product Development Center Hassell: Vaccine Product Development Center: GMP Manufacturing, Toxicology, and Clinical Data Management Haynes: MPER-Peptide Liposome Immunogen Testing Haynes: Protein Expression Facility Himansu: mRNA Encoded Abs for HIV Prophylaxis Ho: First in human clinical evaluation of 10E8.4/iMab, a potent and broad bispecific antibody against HIV
Johnson: Single Cell Transcriptional Profiling of Latently-Infected CD4+ T Cells Jolicoeur: Development of a new class of immunogens for raising broadly neutralizing antibodies
Kamarck: Clinical Assessment of Live Attenuated hCMV-HIV Prototype Vector Kim: AVANTI: An Alliance for Vaccine Access, New Technology, and Innovation Koup: Comprehensive Cellular Vaccine Immune Monitoring Consortium Kublin: HVTN 705: A phase 2b clinical trial to evaluate the efficacy of Ad26 recombinant HIV vaccine + gp140
McElrath: Durability of HIV-specific protective Ab responses in human immunology-based experimental medicine trials Montefiori: Ab VIMC Moore: Next generation BG505 SOSIP.664-trimer based lineage HIV vaccines
Ndung’u: Profiling Virus Neutralization in the KwaZulu-Natal FRESH Cohort Nussenzweig: Clinical Trial of Broadly Neutralizing anti-HIV Antibodies Nussenzweig: Phase 1 studies of the pharmacokinetics, safety, and bioactivity of 3BNC117-LS and 10-1074-LS among adults in the US and sub-Saharan Africa
Pettit: Just Biotherapeutics Support for HIV bNAbs Picker: An Attenuated CMV Vector Picker: MHC II and MHC E-Restricted CD8+ T Cells and Control of HIV Pulendran: Protective humoral responses against HIV
Sajadi: Development of a new family of potent and broad neutralizing antibodies Sanders: HIV Trimer Immunogens to Elicit bNAbs against Multiple EpitopesShaw: Germline targeted SOSIPs and SHIVs to elicit V2 apex bNAbs
Sajadi: Development of a new family of potent and broad neutralizing antibodies
Sanders: HIV Trimer Immunogens to Elicit bNAbs against Multiple Epitopes
Shaw: Germline targeted SOSIPs and SHIVs to elicit V2 apex bNAbs
Ward: Establishment of an Analytics Network to Support Qualified/Validated Assays Required for Characterization of HIV Env Immunogens